New clarivate report identifies trends in gene therapy poised to impact patients, payers, regulators and developers

Report explores how developers are addressing challenges to market approvals and payment london , may 2, 2023 /prnewswire/ -- clarivate plc (nyse: clvt), a global leader in connecting people and organizations to intelligence they can trust to transform their world, announced the release of its new report, making gene therapy work for patients, payers, regulators and developers: five key trends in gene therapy approvals and access . the report explores the challenges and triumphs of gene therapy, with an eye on how developers are addressing risk and the need for multiple modalities and how payers are exploring alternative pay methods.
CLVT Ratings Summary
CLVT Quant Ranking